Novel approaches in the treatment of allergic rhinitis

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 1, 2003, Pages 21-27

  Schultz, Armin ^a   Alexander Stuck, Boris ^a   Feuring, Martin ^a   Hörmann, Karl ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergic rhinitis; Drug therapy

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CORTICOSTEROID; DECONGESTIVE AGENT; DESLORATADINE; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; TERFENADINE;

ALLERGIC RHINITIS; ASTHMA; IMMUNOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

ADMINISTRATION, INTRANASAL; ANTIBODIES; DESENSITIZATION, IMMUNOLOGIC; HEPARIN; HUMANS; IMMUNOGLOBULIN E; LEUKOTRIENE ANTAGONISTS; PHOSPHODIESTERASE INHIBITORS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 12244289674     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200302000-00004     Document Type: Review

References (65)

1. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99(1 Pt 1):22-27.
2. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81 (5 Pt 2):478-518.
3. Kulig M, Klettke U, Wahn V, et al. Development of seasonal allergic rhinitis during the first 7 years of life. J Allergy Clin Immunol 2000; 106:832-839.
4. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002; 88 (Suppl 1):2-7.
5. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15:21-25.
6. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161:2051-2057.
7. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (Suppl 5):S147-S334. This review represents a very comprehensive ARIA workshop report. Over almost 200 pages detailed facts and results about allergic rhinitis and its impact on asthma can be found.
8. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256. This is an important multicentre study with a large patient number, that significantly demonstrates the benefits of specific immunotherapy in preventing the development of asthma.
9. Storms WW. Rethinking our approach to allergic rhinitis management. Ann Allergy Asthma Immunol 2002; 88 (Suppl 1):30-35.
10. Beato M. Steroid hormones, signal transduction, genetic expression, and gynecologic cancer. Med Clin (Barc) 1999; 112:745-754.
11. Falkenstein E, Tillmann HC, Christ M, et al. Multiple actions of steroid hormones: a focus on rapid, nongenomic effects. Pharmacol Rev 2000; 52:513-556.
12. Blaiss MS. Efficacy, safety, and patient preference of inhaled nasal corticosteroids: a review of pertinent published data. Allergy Asthma Proc 2001; 22 (Suppl 1):S5-S10.
13. Dupclay Jr L, Doyle J. Assessment of intranasal corticosteroid use in allergic rhinitis: benefits, costs, and patient preferences. Am J Manag Care 2002; 8 (Suppl):S335-S340.
14. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89:292-297.
15. Pullerits T, Praks L, Skoogh BE, et al. Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999; 159:1814-1818.
16. Bernstein DI, Creticos PS, Busse WW, et al. Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1996; 97:749-755.
17. Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med 2001; 161:2581-2587.
18. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:949-955. A double-blind, randomized study which shows superiority of the intranasal glucocorticoid fluticasone over an LTRA (montelukast) and concomitant anti-histamine (loratadine) and an LTRA.
19. Gelfand EW, Cui ZH, Takeda K, et al. Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2002; 110:85-95.
20. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000; 105 (6 Pt 2):S622-S627.
21. DuBuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999; 21:281-295.
22. Ciprandi G, Cosentino C, Milanese M, et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56:1068-1070. This pilot study showed efficacy of fexofenadine in perennial allergic rhinitis, both on total symptom score and nasal congestion.
23. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001; 56:1077-1080. The benefits were demonstrated in a large study population of 346 patients and could be observed from the first evaluation on day 2 and continued over the entire duration of the study.
24. Horak F, Stubner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002; 109:956-961. This study showed that desloratadine not only significantly improves nasal symptom scores but also significantly reduces the severity of nasal obstruction.
25. Borish L, The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 2002; 88 (Suppl 1):16-22.
26. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16:289-297.
27. Okuda M, Watase T, Mezawa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988; 60:537-540.
28. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001; 56 (Suppl 66): 7-11.
29. Diamant Z, Fokkens WJ. Leukotriene receptor antagonists: clinical potential in allergic rhinitis. Rhinology 2001; 39:187-190.
30. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323:1745-1748.
31. Donnelly AL, Glass M, Minkwitz MC, et al. The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151:1734-1739.
32. Flowers BK, Proud D, Kagey-Sobotka A, et al. The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990; 102:219-224.
33. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32:1020-1028. This was a placebo and active-controlled study in 1302 patients, who received either montelukast, loratadine (as active control) or placebo, but without the intention to compare montelukast and loratadine. Montelukast improved daytime and night-time symptoms and quality-of-life parameters and in contrast to loratadine, significantly reduced peripheral blood eosinophil count.
34. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebocontrolled clinical trial. J Allergy Clin Immunol 2000; 105:917-922.
35. Wilson AM, Orr LC, Coutie WJ, et al. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32:126-132. This study demonstrated that both treatment regimes were equally effective and improved significantly peak inspiratory flow and nasal symptoms.
36. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicentre, randomized, double-blind, placebo; controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88:592-600. A large clinical study with 907 patients in four treatment groups, receiving either montelukast, loratadine, combined montelukast with loratadine or placebo. All active arms were superior to placebo; concomitant therapy, however, did not demonstrate significant improvements compared to monotherapy.
37. Wilson AM, White PS, Gardiner Q, et al. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in a real life rhinology clinic setting. Rhinology 2001; 39:142-146.
38. Wilson AM, Sims EJ, Orr LC, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87:344-349.
39. Giembycz MA. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here? Drugs 2000; 59:193-212.
40. Schudt C, Gantner F, Tenors H, et al. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther 1999; 12:123-129.
41. Schmidt BM, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108:530-536. This was the first study of rofiumilast in allergic rhinitis. Improvements of objective and subjective parameters could be demonstrated. Statistical significance, however, was only achieved at the last study day.
42. Baraniuk JN, Tai CF. Inhibition of phosphodiesterase 4 in allergic rhinitis. Curr Allergy Asthma Rep 2002; 2:191-192.
43. Matzner Y, Marx G, Drexler R, et al. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984; 52:134-137.
44. Ekre HP, Fjellner B, Hagermark O. Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 1986; 8:277-286.
45. Lider O, Mekori YA, Miller T, et al. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 1990; 20:493-499.
46. Ahmed T, Abraham WM, d'Brot J. Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep. Am Rev Respir Dis 1992; 145:566-570.
47. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 1993; 147:160-163.
48. Diamant Z, Timmers MC, van der Veen H, et al. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med 1996; 153 (6 Pt 1):1790-1795.
49. Vancheri C, Mastruzzo C, Armato F, et al. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 2001; 108:703-708. Intranasal heparin given before intranasal allergen challenge reduced the symptom score, the eosinophil influx and the amount of eosinophil cationic protein in the nasal wash. However, statistical significance was only reached in some of the measurements.
50. Andre C, Vatrinet C, Galvain S, et al. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-234.
51. Lombardi C, Gargioni S, Melchiorre A, et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicentre post-marketing surveillance study. Allergy 2001; 56:989-992. A 3-year follow-up study with 198 patients showed an adverse event rate of 7.5% and no serious adverse events.
52. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madr) 2001; 29:238-244.
53. Bahceciler NN, Isik U, Barlan IB, et al. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001; 32:49-55.
54. Lombardi C, Gargioni S, Venturi S, et al. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyperreactivity. J Investig Allergol Clin Immunol 2001; 11:41-45.
55. Silvestri M, Spallarossa D, Battistini E, et al. Changes in inflammatory and clinical parameters and in bronchial hyperreactivity in asthmatic children sensitized to house dust mites following sublingual immunotherapy. J Investig Allergol Clin Immunol 2002; 12:52-59.
56. Motta G, Passali D, De Vincentiis I, et al. A multicentre trial of specific local nasal immunotherapy. Laryngoscope 2000; 110:132-139.
57. Marcucci F, Sensi LG, Caffarelli C, et al. Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy 2002; 57:23-28.
58. Olivieri M, Mohaddes Zadeh MR, Talamini G, et al. Local nasal immunotherapy and bronchial hyperreactivity in seasonal allergic rhinitis: an observational pilot study. J Investig Allergol Clin Immunol 2000; 10:300-304.
59. Mellerup MT, Hahn GW, Poulsen LK, et al. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423-1429.
60. Berger WE. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 2002; 88:152-160; quiz 161-162; 208.
61. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
62. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956-2967. The results of this important clinical trial, with a large patient number enrolled, provide evidence that lowering of systemic free immunoglobulin E levels by omalizumab provides clinical benefit in patients with SAR by improving rhinitisspecific quality-of-life and reduction of the use of rescue medication.
63. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253-259.
64. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110:68-71. A nasal biopsy study, which showed that anti-immunoglobulin E treatment has a significant anti-inflammatory effect on cellular markers in blood and nasal tissue.
65. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109:274-280. This large and controlled clinical trial demonstrated that the combination therapy with anti-immunoglobulin E and specific immunotherapy was more effective than immunotherapy alone. Symptom load score was reduced by almost half over specific immunotherapy alone.